

Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response

Charles J. Ryan, Shreya Shah, Eleni Efstathiou, et al.

Clin Cancer Res 2011;17:4854-4861. Published OnlineFirst June 1, 2011.

Updated version Access the most recent version of this article at:
doi:[10.1158/1078-0432.CCR-11-0815](https://doi.org/10.1158/1078-0432.CCR-11-0815)

Cited Articles This article cites by 22 articles, 12 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/17/14/4854.full.html#ref-list-1>

Citing articles This article has been cited by 12 HighWire-hosted articles. Access the articles at:
<http://clincancerres.aacrjournals.org/content/17/14/4854.full.html#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.

Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response

Charles J. Ryan¹, Shreya Shah¹, Eleni Efstathiou², Matthew R. Smith³, Mary-Ellen Taplin⁴, Glenn J. Bubley⁵, Christopher J. Logothetis², Thian Kheoh⁶, Christine Kilian¹, Christopher M. Haqq⁶, Arturo Molina⁶, and Eric J. Small¹

Abstract

Purpose: Abiraterone is an oral inhibitor of CYP17, which is essential for androgen biosynthesis. This multicenter study assessed its efficacy in patients with castration-resistant prostate cancer (CRPC), without prior chemotherapy or CYP17-targeted therapy, and frequency of bone scans discordant with prostate-specific antigen (PSA) and clinical response.

Experimental Design: Thirty-three patients received abiraterone acetate 1,000 mg daily with prednisone 5 mg twice daily in continuous 28-day cycles. Patients were evaluated monthly for efficacy and safety. Bone scan flare was defined as the combination, after 3 months of therapy, of an interpreting radiologist's report indicating "disease progression" in context of a 50% or more decline in PSA level, with scan improvement or stability 3 months later.

Results: A 50% or more decline in PSA level at week 12 was confirmed in 22 of 33 (67%) patients. Declines in PSA level of 50% or more were seen in 26 of 33 (79%) patients. Undetectable PSA levels (≤ 0.1 ng/mL) occurred in 2 patients. Median time on therapy and time to PSA progression were 63 weeks and 16.3 months, respectively. Twenty-three patients were evaluable for bone scan flare. Progression was indicated in radiologist's report in 12 of 23 (52%), and 11 of 12 subsequently showed improvement or stability. As prospectively defined, bone scan flare was observed in 11 of 23 (48%) evaluable patients or 11 of 33 (33%) enrolled patients. Adverse events were typically grade 1/2 and consistent with prior published abiraterone reports.

Conclusion: Clinical responses to abiraterone plus prednisone were frequent and durable in men with metastatic CRPC. Further investigation is needed to clarify the confounding effect of bone scan flare on patient management and interpretation of results. *Clin Cancer Res*; 17(14); 4854–61. ©2011 AACR.

Introduction

As data emerge suggesting that the progression of prostate cancer in an androgen-deprived milieu is, in part, mediated through the selective growth of tumor cells with

a heightened sensitivity to androgens (1–4), progress and interest in the development of therapies that target extragonadal androgen synthesis have accelerated (5, 6). Abiraterone acetate is an orally available selective androgen biosynthesis inhibitor that specifically inhibits CYP17. Abiraterone has shown activity as a monotherapy in castration-resistant prostate cancer (CRPC) in both chemotherapy-naive and chemotherapy-exposed patients receiving a luteinizing hormone-releasing hormone (LHRH) analogue (7–12).

On the basis of the phase I experience with abiraterone acetate monotherapy, it was determined that the safety profile of this therapy could be improved through concomitant corticosteroid administration, an approach that reduces the compensatory elevations in adrenocorticotropic hormone (ACTH) and mineralocorticoid excess induced by CYP17 blockade. Because corticosteroids have shown modest antitumor efficacy when given as monotherapy, the current phase II study was designed to determine the efficacy and safety of the combination of abiraterone acetate and prednisone in patients with metastatic CRPC. In particular,

Authors' Affiliations: ¹Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; ²MD Anderson Cancer Center, Houston, Texas; ³Division of Hematology-Oncology, Massachusetts General Hospital; ⁴Dana-Farber Cancer Institute; ⁵Beth Israel Deaconess Medical Center, Boston, Massachusetts; and ⁶Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California

Note: Presented in part at the 2009 American Society of Clinical Oncology Annual Meeting, Orlando, Florida, and the 2009 American Society of Clinical Oncology Genitourinary Cancers Symposium, Orlando, Florida.

Corresponding Author: Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero Street, San Francisco, CA 94115. Phone 415-353-9279; Fax: 415-353-7779; E-mail: ryanc@medicine.ucsf.edu

doi: 10.1158/1078-0432.CCR-11-0815

©2011 American Association for Cancer Research.

Translational Relevance

Castration-resistant prostate cancer (CRPC) is a lethal disease and depends on androgen production and androgen receptor signaling for growth, affecting bone more than other distant sites. Abiraterone acetate, a selective androgen biosynthesis inhibitor of CYP17, has been shown to inhibit persistent androgen synthesis from adrenal and intratumoral sources, thereby suppressing an important stimulus of CRPC growth. This phase II study is the first assessment of abiraterone acetate in CRPC not previously treated with docetaxel or androgen synthesis inhibitors such as ketoconazole. Serial changes in objective imaging (i.e., bone scans) were utilized to assess patient outcomes. Discordant findings between serologic (prostate-specific antigen) response and increases in bone scan lesion intensity, although previously described in treatment-naïve prostate cancer, are reported here for the first time in CRPC. In addition to reporting prolonged antitumor activity of abiraterone acetate, this study highlights the potential detriment for patients if increased bone scan intensity is erroneously interpreted as disease progression.

the present trial is the first trial with abiraterone to focus on patients who had not been treated with either docetaxel or an androgen synthesis inhibitor, such as ketoconazole.

A well-recognized barrier to therapy development in CRPC is the lack of reliable surrogate markers of response to treatment coupled with a potentially exaggerated reliance on changes in serum prostate-specific antigen (PSA) as an indicator of treatment efficacy. This is particularly true with agents that have the potential for PSA modulation such as abiraterone acetate or ketoconazole. Consequently, changes in bone scan images have been advocated as important markers of disease response and progression. However, the utility of bone scans has been called into question because of a transient "flare" of bone lesion intensity in the context of treatment response resulting in a false determination of disease progression (13, 14). Although the bone scan flare has been described in breast cancer and in hormone-sensitive prostate cancer, no systemic evaluation of the flare phenomenon has been undertaken in CRPC (15, 16). Therefore, changes in objective imaging, particularly bone scans, were incorporated into this study in addition to PSA decline and time to PSA progression. As noted, these imaging changes are particularly important in the context of a novel agent that can potentially modulate PSA, potentially rendering it a less useful biomarker.

Patients and Methods

Patients

Eligibility required histologically confirmed adenocarcinoma of the prostate progressing on androgen deprivation

therapy (either an LHRH agonist or orchiectomy, and following antiandrogen withdrawal, as appropriate). PSA progression was defined according to Prostate-Specific Antigen Working Group (PSAWG) criteria (17), and all patients had to have baseline lesions identified by bone scan, computed tomography (CT), or MRI. Prior ketoconazole therapy or chemotherapy was not permitted, with the exception of neoadjuvant or adjuvant chemotherapy completed at least 1 year before study entry. Additional eligibility criteria included an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, adequate renal [serum creatinine $\leq 1.5 \times$ upper limit of normal (ULN)], hepatic [bilirubin $\leq 1.5 \times$ ULN, aspartate aminotransferase and alanine aminotransferase $\leq 2.5 \times$ ULN], and bone marrow (hemoglobin >9 gm/dL, absolute neutrophil count $>1.5 \times 10^9/L$, platelets $>100 \times 10^9/L$) function, serum potassium level 3.5 mmol/L or more, and a castrate level of testosterone (<50 ng/dL). Patients with clinically significant electrocardiogram (ECG) abnormalities were ineligible, as were patients with uncontrolled hypertension, New York Heart Association Class III or IV congestive heart failure, those with active autoimmune disease requiring corticosteroid therapy, or any other serious medical or psychiatric illness. Radiation therapy or initiation of bisphosphonate therapy within 4 weeks of study entry was not permitted, although maintenance of a stable bisphosphonate dose was allowed. Use of hormonal therapies, systemic corticosteroids, or any other agent known to decrease PSA levels within 4 weeks prior to study initiation was not permitted. Written informed consent was obtained from all patients.

Treatment and evaluations

Treatment consisted of abiraterone acetate 1,000 mg daily with prednisone 5 mg twice daily. Abiraterone was administered without food in 28-day cycles. Treatment was given continuously until there was evidence of disease progression in patients not experiencing unacceptable toxicity.

Screening evaluations included a history and physical examination, performance status evaluation, and a 12-lead ECG. Laboratory assessments included complete blood cell count, serum chemistries and electrolytes, blood clotting evaluation (prothrombin time, partial thromboplastin time, international normalized ratio), and serum PSA and testosterone levels. Baseline tumor imaging was done by bone scan, CT, MRI, or other imaging procedure. Selected physical and laboratory assessments were repeated on days 1 and 8 of cycle 1, on day 1 of each subsequent cycle, and at the end of study. PSA values were obtained monthly. Adverse events were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3. Bone scans and tumor imaging studies were repeated every 3 cycles.

Study design and statistical considerations

This was a single-arm, open-label, multicenter phase II study conducted under the auspices of the Department of

Defense Prostate Cancer Clinical Trials consortium and sponsored by Cougar Biotechnology. The primary study endpoint was the proportion of patients achieving a 50% or more decline in PSA levels by week 12 of therapy. Secondary endpoints included durability of response as determined by time to PSA progression, objective radiographic response rate according to RECIST guidelines (18), radiographic progression-free survival time, overall survival time, clinical benefit as determined by disease stabilization, change in ECOG performance status, and overall treatment safety.

Bone scan flare was prospectively defined as discordant results after 3 months of therapy based on the combination of an interpreting radiologist's report indicating "disease progression," typically based on increased lesion intensity or number that occurred in the context of a 50% or more decline in PSA levels, which on subsequent reevaluation 3 months later showed improvement or stability in the scan. Thus, patients evaluable for bone scan flare included all patients who had bone scans available at baseline, after 3 months of therapy, and after 6 months of therapy. An initial flare at 3 months followed by continued declines in PSA levels and *stable* scans was also considered to be of interest and is reported separately from true flare.

A sample size of 32 evaluable patients was determined as necessary to detect a response rate of 50% or more, with response defined as 50% or more decline in PSA levels at 12 weeks from baseline measurement, at a significance level of 0.04 for a directional test and 81% power. Distributions of time-to-event variables were estimated using the Kaplan-Meier product limit method. All patients who received a minimum of 3 cycles of therapy were considered evaluable for response. All patients who received at least 1 dose of abiraterone acetate were evaluable for safety.

Adverse events were summarized by worst grade of severity per patient. The study protocol was approved by the institutional review boards at all participating sites and was conducted in accordance with the ethical principles of the World Medical Association Declaration of Helsinki.

Results

Patient characteristics and treatment

Between October 2007 and May 2008, a total of 33 men with metastatic prostate cancer progressing despite a castrate level of testosterone were enrolled across 5 study centers within the United States. Baseline patient demographics and clinical characteristics are shown in Table 1. The median baseline PSA level was 23 ng/mL and ranged from 5.9 to 1,110 ng/mL. All patients had radiographic evidence of metastatic disease and 26 of 33 (79%) had bony metastases. All patients had received androgen deprivation therapy with an LHRH antagonist ($N = 31$) or orchiectomy ($N = 2$), and 32 (97%) had also received an antiandrogen and undergone antiandrogen withdrawal. All patients had castrate serum testosterone levels (median 8.5 ng/dL; range, 0.9–24.1 ng/dL). The

Table 1. Baseline demographic and clinical characteristics of 33 patients enrolled in a phase II trial of abiraterone acetate plus prednisone

	Baseline value
PSA, median (range), ng/mL	23.0 (5.9–1,110.0)
Metastases, <i>n</i> (%)	
Visceral only	1 (3)
Viscera plus bone/soft tissue	2 (6)
Bone only	10 (30.3)
Soft tissue only	6 (18.2)
Bone and soft tissue only	14 (42.4)
Gleason score, median (range)	8 (5–9)
Hemoglobin, median (range), g/dL	12.8 (10.6–15.3)
Testosterone, median (range), ng/dL	25.5 (4.0–49.0)
Alkaline phosphatase, median (range), units/L	82.0 (39.0–1,078.0)
Number of hormonal therapies, median (range)	2 (2–4)


majority of patients (88%) had received 2 prior hormonal therapies, with 3 patients (9%) having received up to 4 hormonal therapies including estrogens or glucocorticoids. No patient had undergone prior treatment with abiraterone, ketoconazole, or chemotherapy. At the time of analysis (January 2010), the study population had received a median of 63 weeks (range, 8–104 weeks) of treatment with abiraterone acetate plus prednisone, with 15 patients (46%) continuing to receive therapy. Treatment had been discontinued secondary to disease progression in 14 patients (42%) and adverse events in 3 patients (9%); 2 patients discontinued treatment as a result of grade 3 adverse events (1 each for back pain and pathologic fracture). Twenty-three patients were evaluable for the bone flare phenomenon. All 33 patients were evaluable for response and safety.

PSA response and durability

Changes in PSA levels, both after 3 months of therapy and maximal, for each patient are depicted in Figure 1. A decline in PSA level of 50% or more after 3 months, the primary study endpoint, was confirmed in 22 (67%) of 33 patients. Confirmed maximal declines in PSA levels of 50% or more and 90% or more were seen in 26 (79%) and 15 (46%) patients, respectively. In 2 patients, PSA levels became undetectable (≤ 0.1 ng/mL), declining from baseline values of 204 ng/mL and 9 ng/mL, respectively. These patients continued to receive study therapy after 20 and 21 months, both with continued stable bone scans and resolution of adenopathy in 1 patient.

Median follow-up time for this analysis was 19.3 months. The median time to PSA progression was 16.3

Figure 1. Changes in PSA levels in CRPC patients treated with abiraterone acetate plus prednisone. Waterfall plots of maximal PSA change (top) and PSA change at week 12 (bottom). Reference lines: black, -90%; orange, -50%; green, -30%.



months [95% CI 9.2 months, not estimable; Fig. 2]. Nineteen (58%) patients received study treatment for at least 12 months.

Objective tumor response

Of 13 patients with measurable disease consisting of lymphadenopathy, 9 (69%) had a partial response and 3 (23%) had stable disease.

Bone scan results and bone scan flare

At baseline, 26 patients had positive bone scans. One had a solitary bone metastasis, 7 patients had between 2 and 4 metastases, and 18 patients had more than 4 discrete metastases. Twenty-three patients had the combination of a positive baseline bone scan, a 50% or more decline in PSA after 3 months, and bone scans at 3 and 6 months and thus were available for evaluation of bone scan flare. Reports were available on 92 total bone scans from 41 unique

radiologists dispersed geographically among the study sites. Of the 23 eligible patients, bone scan progression was indicated in the radiologists' reports in 12 (52%) of the scans taken after 3 months of therapy. Four of the 12 patients had a report worded specifically as "progression of disease" without new lesions (e.g., based solely on increased intensity of existing lesions), whereas for 8 of 12 patients, progression of disease due to new lesions was noted. For imaging following 6 months of therapy, the radiologists' reports indicated subsequent improvement in 4 of 12 and stability in 7 of 12 patients. One patient had a worsened scan at 6 months despite continued PSA decline, showing a new lesion. Thus, overall, bone scan flare, as defined by the combination of PSA decline, initial flare, and subsequent improvement or stability in bone scans at 6 months, was observed in 4 of 23 (17%) and 7 of 23 (30%) evaluable patients and 4 of 33 (12%) and 7 of 33 (21%) enrolled patients, respectively.

Two responding patients were not evaluable for bone scan flare: 1 had persistent declines in PSA levels (from baseline to the end of month 3 and from month 3 through month 6 of therapy), with a negative bone scan at baseline that was not repeated; the second discontinued study therapy after 4 months on therapy because of a pathologic femoral neck fracture despite a decline in PSA level of 91.7%.

In the 11 patients with bone flare at 3 months and stable or improved scans at 6 months, median age was 72 years (range, 54-85), median PSA level at baseline was 21.9 ng/dL (range, 6.8-204.3), and median alkaline phosphatase level at baseline was 88.5 units/L (range, 49.0-372.0), not significantly different from the study population as a whole. Alkaline phosphatase levels did not change in patients experiencing flare: median baseline value was 88.5 units/L. After 3 months of therapy, the median remained at 88.5 units/L and after 6 months, it was 83.5 units/L. Four patients had less than 4 metastases,




Figure 2. Time to PSA progression in CRPC patients treated with abiraterone acetate and prednisone (N = 33). NE, not estimable.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.